Xenon Pharmaceuticals Inc...

30.70
-0.76 (-2.42%)
At close: Apr 03, 2025, 3:59 PM
29.75
-3.08%
Pre-market: Apr 04, 2025, 04:49 AM EDT

Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials.

It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain.

Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. logo
Country CA
IPO Date Nov 5, 2014
Industry Biotechnology
Sector Healthcare
Employees 316
CEO Ian C. Mortimer C.M.A., CPA, M.B.A.

Contact Details

Address:
3650 Gilmore Way
Burnaby, BC
CA
Website https://www.xenon-pharma.com

Stock Details

Ticker Symbol XENE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001582313
CUSIP Number 98420N105
ISIN Number CA98420N1050
Employer ID 98-0661854
SIC Code 2834

Key Executives

Name Position
Ian C. Mortimer C.M.A., CPA, M.B.A. President, Chief Executive Officer & Director
Andrea DiFabio J.D. Chief Legal Officer & Corporate Secretary
Sherry Aulin C.A., CPA Chief Financial Officer
Dr. Christopher John Kenney M.D. Chief Medical Officer
Dr. James R. Empfield Ph.D. Executive Vice President of Drug Discovery
Dr. Robin P. Sherrington Ph.D. Executive Vice President of Strategy & Innovation
Shelley McCloskey B.A. Executive Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 17, 2025 8-K Current Report
Mar 13, 2025 4 Filing
Mar 13, 2025 4 Filing
Mar 13, 2025 4 Filing
Mar 07, 2025 SCHEDULE 13G/A [Amend] Filing
Mar 05, 2025 8-K Current Report
Feb 27, 2025 S-8 Filing
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Jan 27, 2025 4 Filing